InvestorTalk Alert: Brent Willis from Voyageur Pharmaceuticals Ltd. to host on Thursday, September 11, 2025

InvestorNews.com is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Thursday, September 11^th, at 9:00 AM EST, featuring Brent Willis, President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please click here

Voyageur is developing barium and iodine Active Pharmaceutical Ingredients (API) for cost-effective, high-performance imaging contrast agents. With a strategy to vertically integrate these markets, Voyageur plans to produce its own barium and iodine and is also advancing new endo fullerene drugs. Its business plan begins with sales through partnerships with third-party GMP pharmaceutical manufacturers in Canada, ensuring global regulatory validation, before transitioning into a high-margin domestic manufacturer of radiology drugs. Voyageur owns 100% of the Frances Creek barium sulphate (barite) project, a rare high-grade mineral resource suitable for pharmaceutical use. Unlike current synthetic products, Voyageur believes its barite will deliver superior imaging quality. The company’s goal is to be the first vertically integrated radiology contrast media producer, controlling raw material sourcing through final production—living its motto: “From the Earth to the Bottle.”

In preparation for tomorrow’s InvestorTalk, here are some recent news releases from Voyageur Pharmaceuticals for your review, which are listed below:

• August 25, 2025 – Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform — click here
• August 21, 2025 – Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics — click here
• August 19, 2025 – Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million — click here

We found the August 25^th news release titled, “Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform” particularly noteworthy and here are 5 key data points from it:

• Iodine Feasibility Study Launched (U.S.): Voyageur Pharmaceuticals has initiated a U.S.-based iodine feasibility program aimed at establishing the first fully integrated North American iodine contrast drug manufacturing platform.
• Streamline Process & Bench Testing: The study begins with bench-scale testing of iodine-rich oilfield brine water to validate the technical and economic viability of iodine extraction, using Voyageur’s proprietary “Streamline Process,” in collaboration with third-party engineering experts.
• Pilot Plant & Production Goals: Plans include deploying a pilot 200-tonne-per-year iodine extraction unit, with potential to scale production to 1,000 tonnes annually. Current iodine flake prices are about US$70,000/tonne.
• Full Supply Chain Integration: The project supports Voyageur’s strategy to vertically integrate radiology contrast media from raw mineral extraction (barium and iodine) through to drug manufacturing, reducing reliance on foreign supply chains dominated by Europe and China.
• National Security & Market Demand: With 3.6 billion diagnostic exams conducted annually worldwide and demand for iodinated contrast media expected to double in the next decade, Voyageur is positioning itself to secure domestic supply, supported by U.S. government funding programs and partnerships with iodine contrast media companies.

For more information on Voyageur Pharmaceuticals Ltd., click here

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.